252 related articles for article (PubMed ID: 33549556)
1. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF.
Ferreira JP; Verdonschot J; Wang P; Pizard A; Collier T; Ahmed FZ; Brunner-La-Rocca HP; Clark AL; Cosmi F; Cuthbert J; Díez J; Edelmann F; Girerd N; González A; Grojean S; Hazebroek M; Khan J; Latini R; Mamas MA; Mariottoni B; Mujaj B; Pellicori P; Petutschnigg J; Pieske B; Rossignol P; Rouet P; Staessen JA; Cleland JGF; Heymans S; Zannad F;
JACC Heart Fail; 2021 Apr; 9(4):268-277. PubMed ID: 33549556
[TBL] [Abstract][Full Text] [Related]
2. Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial.
Verdonschot JAJ; Ferreira JP; Pellicori P; Brunner-La Rocca HP; Clark AL; Cosmi F; Cuthbert J; Girerd N; Mariottoni B; Petutschnigg J; Rossignol P; Cleland JGF; Zannad F; Heymans SRB;
Cardiovasc Diabetol; 2021 Aug; 20(1):163. PubMed ID: 34372849
[TBL] [Abstract][Full Text] [Related]
3. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial.
Pellicori P; Ferreira JP; Mariottoni B; Brunner-La Rocca HP; Ahmed FZ; Verdonschot J; Collier T; Cuthbert JJ; Petutschnigg J; Mujaj B; Girerd N; González A; Clark AL; Cosmi F; Staessen JA; Heymans S; Latini R; Rossignol P; Zannad F; Cleland JGF
Eur J Heart Fail; 2020 Sep; 22(9):1711-1723. PubMed ID: 31950604
[TBL] [Abstract][Full Text] [Related]
4. Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial.
Ferreira JP; Verdonschot JAJ; Girerd N; Bozec E; Pellicori P; Collier T; Mariottoni B; Cosmi F; Hazebroek M; Cuthbert J; Petutschnigg J; Heymans S; Staessen JA; Pieske B; Edelman F; Clark AL; Díez J; González A; Rossignol P; Cleland JG; Zannad F
Eur J Heart Fail; 2022 May; 24(5):771-778. PubMed ID: 35199421
[TBL] [Abstract][Full Text] [Related]
5. Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort.
Kobayashi M; Ferreira JP; Duarte K; Bresso E; Huttin O; Bozec E; Brunner La Rocca HP; Delles C; Clark AL; Edelmann F; González A; Heymans S; Pellicori P; Petutschnigg J; Verdonschot JAJ; Rossignol P; Cleland JGF; Zannad F; Girerd N;
Eur J Heart Fail; 2024 May; 26(5):1231-1241. PubMed ID: 38528728
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study.
Myhre PL; Vaduganathan M; O'Meara E; Claggett BL; de Denus S; Jarolim P; Anand IS; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS
Circ Heart Fail; 2020 Jan; 13(1):e006638. PubMed ID: 31957468
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial.
Verdonschot JAJ; Ferreira JP; Pizard A; Pellicori P; Brunner La Rocca HP; Clark AL; Cosmi F; Cuthbert J; Girerd N; Waring OJ; Henkens MHTM; Mariottoni B; Petutschnigg J; Rossignol P; Hazebroek MR; Cleland JGF; Zannad F; Heymans SRB;
J Card Fail; 2022 May; 28(5):778-786. PubMed ID: 34933097
[TBL] [Abstract][Full Text] [Related]
8. A machine learning-derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: Findings from the HOMAGE trial.
Kobayashi M; Huttin O; Ferreira JP; Duarte K; González A; Heymans S; Verdonschot JAJ; Brunner-La Rocca HP; Pellicori P; Clark AL; Petutschnigg J; Edelmann F; Cleland JG; Rossignol P; Zannad F; Girerd N;
Eur J Heart Fail; 2023 Aug; 25(8):1284-1289. PubMed ID: 37062878
[TBL] [Abstract][Full Text] [Related]
9. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
[TBL] [Abstract][Full Text] [Related]
10. Dyskalemia in people at increased risk for heart failure: findings from the heart 'OMics' in AGEing (HOMAGE) trial.
Monzo L; Ferreira JP; Cleland JGF; Pellicori P; Mariottoni B; Verdonschot JAJ; Hazebroek MR; Collier TJ; Cuthbert JJ; Pieske B; Edelmann F; Petutschnigg J; Khan J; Ahmed FZ; Girerd N; Bozec E; Díez J; González A; Clark AL; Cosmi F; Staessen JA; Heymans S; Rossignol P; Zannad F
ESC Heart Fail; 2022 Dec; 9(6):4352-4357. PubMed ID: 36065795
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.
Desai AS; Lewis EF; Li R; Solomon SD; Assmann SF; Boineau R; Clausell N; Diaz R; Fleg JL; Gordeev I; McKinlay S; O'Meara E; Shaburishvili T; Pitt B; Pfeffer MA
Am Heart J; 2011 Dec; 162(6):966-972.e10. PubMed ID: 22137068
[TBL] [Abstract][Full Text] [Related]
12. Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.
Ferreira JP; Collier T; Clark AL; Mamas MA; Rocca HB; Heymans S; González A; Ahmed FZ; Petutschnigg J; Mujaj B; Cuthbert J; Rouet P; Pellicori P; Mariottoni B; Cosmi F; Edelmann F; Thijs L; Staessen JA; Hazebroek M; Verdonschot J; Rossignol P; Girerd N; Cleland JG; Zannad F
Eur Heart J Cardiovasc Pharmacother; 2022 Feb; 8(2):149-156. PubMed ID: 33822033
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial.
Butler J; Anstrom KJ; Felker GM; Givertz MM; Kalogeropoulos AP; Konstam MA; Mann DL; Margulies KB; McNulty SE; Mentz RJ; Redfield MM; Tang WHW; Whellan DJ; Shah M; Desvigne-Nickens P; Hernandez AF; Braunwald E;
JAMA Cardiol; 2017 Sep; 2(9):950-958. PubMed ID: 28700781
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients.
MacFadyen RJ; Barr CS; Struthers AD
Cardiovasc Res; 1997 Jul; 35(1):30-4. PubMed ID: 9302344
[TBL] [Abstract][Full Text] [Related]
16. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
Cleland JGF; Ferreira JP; Mariottoni B; Pellicori P; Cuthbert J; Verdonschot JAJ; Petutschnigg J; Ahmed FZ; Cosmi F; Brunner La Rocca HP; Mamas MA; Clark AL; Edelmann F; Pieske B; Khan J; McDonald K; Rouet P; Staessen JA; Mujaj B; González A; Diez J; Hazebroek M; Heymans S; Latini R; Grojean S; Pizard A; Girerd N; Rossignol P; Collier TJ; Zannad F;
Eur Heart J; 2021 Feb; 42(6):684-696. PubMed ID: 33215209
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
[TBL] [Abstract][Full Text] [Related]
18. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.
Rousseau MF; Gurné O; Duprez D; Van Mieghem W; Robert A; Ahn S; Galanti L; Ketelslegers JM;
J Am Coll Cardiol; 2002 Nov; 40(9):1596-601. PubMed ID: 12427411
[TBL] [Abstract][Full Text] [Related]
19. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
Ravassa S; Trippel T; Bach D; Bachran D; González A; López B; Wachter R; Hasenfuss G; Delles C; Dominiczak AF; Pieske B; Díez J; Edelmann F
Eur J Heart Fail; 2018 Sep; 20(9):1290-1299. PubMed ID: 29709099
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
